Salarius Pharmaceuticals, Inc.

NasdaqCM:SLRX 주식 보고서

시가총액: US$2.2m

Salarius Pharmaceuticals 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

David Arthur

최고 경영자

US$544.6k

총 보상

CEO 급여 비율91.8%
CEO 임기5.3yrs
CEO 소유권0.4%
경영진 평균 재임 기간데이터 없음
이사회 평균 재임 기간5.3yrs

최근 관리 업데이트

Recent updates

Salarius pharmaceuticals announces 1-for-25 reverse stock split

Oct 14

Salarius adds 12% after updates on clinical programs and financials

Sep 13

Salarius Pharma adds two Mayo Clinic sites to phase 1/2 trial of Seclidemstat as treatment for cancers

Aug 22

Salarius Pharmaceuticals GAAP EPS of -$0.09 beats by $0.01

Aug 08

Salarius Pharmaceuticals and VolitionRx enter into R&D collaboration agreement

Aug 02

Salarius Pharma reports new seclidemstat results in Ewing sarcoma and other solid tumors at ASCO21

Jun 07

Salarius Pharmaceuticals (SLRX) Investor Presentation - Slideshow

May 27

Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain

Feb 09
Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain

Salarius Pharmaceuticals receives second installment of $1.7M in payments

Jan 13

Salarius Pharma raises $3.5M via warrant exercise

Dec 11

Salarius Pharmaceuticals EPS in-line, beats on revenue

Nov 11

CEO 보상 분석

David Arthur 의 보수는 Salarius Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$5m

Jun 30 2024n/an/a

-US$6m

Mar 31 2024n/an/a

-US$9m

Dec 31 2023US$545kUS$500k

-US$13m

Sep 30 2023n/an/a

-US$18m

Jun 30 2023n/an/a

-US$30m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$941kUS$500k

-US$32m

Sep 30 2022n/an/a

-US$29m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021US$677kUS$379k

-US$13m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$9m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$1mUS$340k

-US$8m

Sep 30 2020n/an/a

-US$7m

Jun 30 2020n/an/a

-US$8m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019US$518kUS$315k

-US$7m

Sep 30 2019n/an/a

-US$6m

Jun 30 2019n/an/a

-US$4m

Mar 31 2019n/an/a

-US$3m

Dec 31 2018US$275kUS$258k

-US$2m

보상 대 시장: David 의 총 보상 ($USD 544.60K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 646.00K ).

보상과 수익: David 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

David Arthur (61 yo)

5.3yrs

테뉴어

US$544,600

보상

Mr. David J. Arthur, M.B.A., has been President at Salarius Pharmaceuticals, Inc since July 19, 2019 and Chief Executive Officer & Director at Salarius Pharmaceuticals, Inc. since July 2019. Mr. Arthur ser...


이사회 구성원

이름위치테뉴어보상소유권
David Arthur
CEO, President & Director5.3yrsUS$544.60k0.43%
$ 9.3k
Jonathan Lieber
Independent Director4.4yrsUS$53.76k0.026%
$ 559.5
Bruce McCreedy
Independent Director5.3yrsUS$45.26k0.012%
$ 273.6
Arnold Hanish
Independent Director5.3yrsUS$67.26k0.029%
$ 626.3
William McVicar
Chairman of the Board5.3yrsUS$82.26k0.025%
$ 542.6
Tess Burleson
Independent Director5.3yrsUS$64.76k0.024%
$ 516.8

5.3yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: SLRX 의 이사회경험(평균 재직 기간 5.3 년)으로 간주됩니다.